Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
AbbVie
3,000 participants
Sep 24, 2024
OBSERVATIONAL
Conditions
Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Eligibility
Inclusion Criteria2
- Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
- Participants prescribed atogepant in accordance with the approved local label.
Exclusion Criteria2
- Participants with any contraindication to atogepant as listed on the latest approved local label.
- Participants currently participating in another clinical research except observational study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Tablet
Locations(36)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06603558